Evidence map›Paper›PMID 38213298›Full record

ArticleCancer discovery2024

Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li-Fraumeni Syndrome?

Alicia Latham, Suzanne P MacFarland, Michael F Walsh, Kara N Maxwell, Zsofia K Stadler

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alicia LathamDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9758-713X
Suzanne P MacFarlandThe Department of Pediatrics at CHOP and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-5894-6403
Michael F WalshDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5006-6778
Kara N MaxwellDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8192-4202
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6985-2864
Memorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryIn the first prospective study evaluating circulating tumor DNA (ctDNA) for early cancer detection, Wong, Luo, and colleauges demonstrate the feasibility of liquid biopsy as an augmentation to current surveillance protocols for patients with Li-Fraumeni syndrome, an inherited cancer predisposition associated with high cancer risk in both pediatric and adult populations. Though additional clinical validation in larger cohorts is needed, this research highlights that a multimodal approach is likely necessary to improve the sensitivity of liquid biopsy assays for early cancer detection. See related article by Wong, Lou et al., p. 104 (9).

Indexed as

Cell-Free Nucleic AcidsLi-Fraumeni SyndromeAdultChildGenetic Predisposition to DiseaseGerm-Line MutationHumansLiquid BiopsyProspective StudiesTumor Suppressor Protein p53Cell-Free Nucleic AcidsTumor Suppressor Protein p53

Identifiers

PMID38213298
OpenAlexW4390794171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.